Pituitary gland: Medical therapy for acromegaly: can we predict response?
Response to medical therapy for acromegaly is highly variable, with few predictive factors available to help clinicians make informed treatment choices. Researchers in the UK now suggest that prior radiotherapy might influence an individual's response to secondary therapy with dopamine agonists or somatostatin analogs.
Giustina
Andrea
A
Porcelli
Teresa
T
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D018491:Dopamine Agonists / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000172:deficiency; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007986:Luteinizing Hormone / Q000172:deficiency; D011388:Prolactin / Q000097:blood; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018491:Dopamine Agonists; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone